Materials Science and Engineering in Drug Development



Thursday, 12 November 2015
10.00 Welcome and Introductory Remarks
  W. Beckmann, Bayer Technology Service, Leverkusen/D
 set the theme
10.10 Following the particles on their journey from crystallizer to patient
  C. Price, University of Strathclyde, Glasgow/UK
 Multiplicity of solid state forms
design the form
11.10 Selection of solid-state forms for new chemical entities: challenges, opportunities and lessons learned
  C. Saal, Merck KGaA, Darmstadt/D
12.00 Hydrate phases in pharmaceutical development
  B. Baumgartner, Sanofi-Aventis Deutschland GmbH, Frankfurt/D
12.50 Lunch Break
Scientific aspects of solid-state engineering
design the particle
14.00 Polymorphism and solvate formation – potential threats in pharmaceutical industry
  D. Wieckhusen, Novartis Pharma AG, Basel/CH
14.50 The role of API surface chemistry in pharmaceutical processes
  J. Heng, Imperial College London/UK
15.40 Solid form design & crystal habit modification: utilizing crystallographic data to guide experimental design
  S. Chan, Novartis Pharma AG, Basel/CH
16.30 Coffee Break
Molecular modelling aspects of materials science
support via modelling
16.50 Exploring solid forms landscapes with structural informatics
  N. Feeder, CCDC, Cambridge/UK
17.40 Solvate formation and assessment of crystallizability and
assessment of stability of amorphous materials
  A. Florence, CMAC - University of Strathclyde, Glasgow/UK
18.30 End-of-day-1
Conference Dinner at the historical Restaurant "Gerbermuehle",
Gerbermuehlstrasse 105, 60594 Frankfurt



Friday, 13 November 2015
Formulation aspects of material science and engineering – Control of the API physical form
secure the API attributes
08.30 Integrated crystal and particle engineering for developing pharmaceutical tablet
  C. Sun, University of Minnesota, Minneapolis, MN/USA
09.20 The role of particle engineering in formulation design – Link between drug substance and drug product
  R.A. Storey, AstraZeneca R&D, Macclesfield/UK
10.10 Coffee Break
 paneled discussion
10.30 Current topics of material science engineering in drug development and manufacturing
  J.-O. Henck – C. Price – W. Beckmann – B. Baumgartner
12.00 Lunch Break
Material science aspects of solid-solutions of API’s
amorphous materials
13.00 Amorphous organic materials
  L. Yu, University of Wisconsin, Madison, WI/USA
13.50 Industrial perspectives of manufacturing solid dispersions as enabling technology – From early development to commercial manufacturing
  G. Verreck, Johnson & Johnson Pharma R&D, Beerse/B
14.40 Coffee Break
Control strategies of solid state form API attributes in formulation
performance impact on product
15.00 Small-scale approaches for supporting the solid form selection
  J. Rantanen, University of Copenhagen/DK
15.50 What are the critical attributes of APIs which influences formulation microstructure and dominates product functionality ?
  R. Price, University of Bath/UK
16.40 Connecting the API solid form and particle to drug product performance
  M. Ticehurst, Pfizer, Canterbury/UK
17.30 End and farewell



Jetzt Mitglied werden